MaaT Pharma
Develops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments.
Launch date
Employees
Market cap
AUD171m
Enterprise valuation
AUD154m (Public information from Sep 2024)
Share price
€7.3 MAAT.PA
Company register number 808370100
Lyon Auvergne-Rhône-Alpes (HQ)
Authorizing premium user...